---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000041"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-08-06T11:05:02+00:00"
generated_at: "2026-08-06T11:10:41.712851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ligand Q2 royalty rev +32% YoY; raises 2026 adj EPS guidance; closes XOMA deal

## Summary
- Q2 royalty rev $48.0M (+32% YoY); total rev $63.7M (+34%); GAAP EPS $2.22 (vs $0.24); adj EPS $2.37 (vs $1.60).
- 2026 adj EPS guidance raised to $9.00-$9.50 (from $8.50-$9.50); total revenue guidance unchanged at $270M-$310M.
- Completed XOMA Royalty acquisition on July 14 for $39.00/share + CVR; expected to add ~$0.50 to 2026 adj EPS and ~$1.50 to 2027 adj EPS.
- Issued $700M 0% convertible notes due 2031; repurchased 228,859 shares at ~$262/share using $60M of proceeds.
- Cash & short-term investments $1.36B at June 30, up from $733.5M at Dec 31, 2025.

## SEC filing metadata
- accession: 0000886163-26-000041
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-08-06T11:05:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/0000886163-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/lgnd-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000041
- JSON: https://secwatch.observer/filing/0000886163-26-000041.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.